Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:58:58.424Z.
Calculation as of: 2026-10-06T19:58:58.424Z.
Quote observation: 2026-10-06T19:55:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8188a044afb190b383642178377b3b21d317b4c37addc3eac3f31d1e137b7514
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Seer, Inc.
Market Cap
$120.13M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Seer, Inc. (SEER) | $120.13M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.28M | N/A |
| Cibus, Inc. (CBUS)vs › | $120.99M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.90M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.52M | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.98M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.50M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $115.69M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
